2025 Q4 -tulosraportti
64 päivää sitten
‧49 min
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 13 | - | - | ||
| 41 335 | - | - | ||
| 109 | - | - | ||
| 8 556 | - | - | ||
| 19 444 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 3 881 307 | 3 881 307 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 3 881 307 | 3 881 307 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 7.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 24.2. | ||
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 14.5.2025 | ||
2024 Q4 -tulosraportti 25.2.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·20 t sittenCool that the stock is rising on a red stock market day for many other stocks 🥳 I wonder if it's that teacup-chat at the Placera-forum that has contributed?- ·23.4. · MuokattuAsked AI a bit. Got nothing new about the 50 states.. Other than it's probably April - May based on Immunovia's previous talk. It matches the 8-month "sweet spot". Quote: "the NYSDOH review process frequently takes 6–12 months longer than other states." Other aspects worth considering for the next stock price direction are that it could be extra favorable if it coincides with Immunovia's annual general meeting on Wednesday, May 13. But if it's not ready yet, Immunovia needs to keep its cards close to its chest because marketing for New York will set the validation process back, as marketing is strictly forbidden. Other aspects worth noting about it are, quote: "The Psychological 50: Being "Available in all 50 states" allows the company to stop qualifying its marketing. It simplifies the pitch to large national healthcare networks (like Kaiser Permanente or UnitedHealth), who generally won't partner with a lab that can't serve their New York members." "New York Direct-Pay: New York has a massive population of high-net-worth individuals who utilize "concierge medicine." These patients are often willing to pay the $750 - $995 out-of-pocket price while waiting for insurance. Opening New York unlocks this lucrative "cash-pay" segment immediately." "The Synergy: New York approval actually helps the Medicare case. When a company applies for a National Coverage Determination (NCD), having a "clean" 50-state regulatory record prevents administrative delays."
- ·23.4.Pity. But one can probably expect lower daily stock turnover again if the downturn continues in "this way". Now there must surely be some really good news coming soon, right?!!???
- ·21.4. · Muokattuhttps://forum.placera.se/inlagg/52bd8c37-e0eb-4446-a382-8e8fc5d87a80 49 out of 50 states I think it's a bit strange that there was some optimism about New York approval a few days ago. But it has disappeared? It should soon be very close to that event. If one can believe Jeff Borcherding's Q4 optimistic afternoon webcast
- ·16.4. · MuokattuIs there any source for Adob's claim, or is it just "fluff"? https://forum.placera.se/inlagg/c3b44de5-91bc-4a3a-8c83-92e3f7116c98 Quotes: "Adob > Immunovia 1 hour ago They seem to be in full swing to secure a strategic partner to increase growth EXTREMELY IMPORTANT but they should easily find a partner" "Adob Abbot or Roche would fit well" https://forum.placera.se/inlagg/c3b44de5-91bc-4a3a-8c83-92e3f7116c98
·16.4. · MuokattuThe risk as I see it is that the wolves in the American financial world are smart enough to wait until Immunovia's cash runs out. Then, when they have the knife to their throat, the wolves can "eat up Immunovia" or buy up the company and their patents for a pittance.·16.4.There is always a risk in a price/demand system. I hope that the management of Immunovia are decent and do not facilitate fraud around corporate actions.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
64 päivää sitten
‧49 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·20 t sittenCool that the stock is rising on a red stock market day for many other stocks 🥳 I wonder if it's that teacup-chat at the Placera-forum that has contributed?
- ·23.4. · MuokattuAsked AI a bit. Got nothing new about the 50 states.. Other than it's probably April - May based on Immunovia's previous talk. It matches the 8-month "sweet spot". Quote: "the NYSDOH review process frequently takes 6–12 months longer than other states." Other aspects worth considering for the next stock price direction are that it could be extra favorable if it coincides with Immunovia's annual general meeting on Wednesday, May 13. But if it's not ready yet, Immunovia needs to keep its cards close to its chest because marketing for New York will set the validation process back, as marketing is strictly forbidden. Other aspects worth noting about it are, quote: "The Psychological 50: Being "Available in all 50 states" allows the company to stop qualifying its marketing. It simplifies the pitch to large national healthcare networks (like Kaiser Permanente or UnitedHealth), who generally won't partner with a lab that can't serve their New York members." "New York Direct-Pay: New York has a massive population of high-net-worth individuals who utilize "concierge medicine." These patients are often willing to pay the $750 - $995 out-of-pocket price while waiting for insurance. Opening New York unlocks this lucrative "cash-pay" segment immediately." "The Synergy: New York approval actually helps the Medicare case. When a company applies for a National Coverage Determination (NCD), having a "clean" 50-state regulatory record prevents administrative delays."
- ·23.4.Pity. But one can probably expect lower daily stock turnover again if the downturn continues in "this way". Now there must surely be some really good news coming soon, right?!!???
- ·21.4. · Muokattuhttps://forum.placera.se/inlagg/52bd8c37-e0eb-4446-a382-8e8fc5d87a80 49 out of 50 states I think it's a bit strange that there was some optimism about New York approval a few days ago. But it has disappeared? It should soon be very close to that event. If one can believe Jeff Borcherding's Q4 optimistic afternoon webcast
- ·16.4. · MuokattuIs there any source for Adob's claim, or is it just "fluff"? https://forum.placera.se/inlagg/c3b44de5-91bc-4a3a-8c83-92e3f7116c98 Quotes: "Adob > Immunovia 1 hour ago They seem to be in full swing to secure a strategic partner to increase growth EXTREMELY IMPORTANT but they should easily find a partner" "Adob Abbot or Roche would fit well" https://forum.placera.se/inlagg/c3b44de5-91bc-4a3a-8c83-92e3f7116c98·16.4. · MuokattuThe risk as I see it is that the wolves in the American financial world are smart enough to wait until Immunovia's cash runs out. Then, when they have the knife to their throat, the wolves can "eat up Immunovia" or buy up the company and their patents for a pittance.·16.4.There is always a risk in a price/demand system. I hope that the management of Immunovia are decent and do not facilitate fraud around corporate actions.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 13 | - | - | ||
| 41 335 | - | - | ||
| 109 | - | - | ||
| 8 556 | - | - | ||
| 19 444 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 3 881 307 | 3 881 307 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 3 881 307 | 3 881 307 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 7.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 24.2. | ||
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 14.5.2025 | ||
2024 Q4 -tulosraportti 25.2.2025 |
2025 Q4 -tulosraportti
64 päivää sitten
‧49 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 7.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 24.2. | ||
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 14.5.2025 | ||
2024 Q4 -tulosraportti 25.2.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·20 t sittenCool that the stock is rising on a red stock market day for many other stocks 🥳 I wonder if it's that teacup-chat at the Placera-forum that has contributed?
- ·23.4. · MuokattuAsked AI a bit. Got nothing new about the 50 states.. Other than it's probably April - May based on Immunovia's previous talk. It matches the 8-month "sweet spot". Quote: "the NYSDOH review process frequently takes 6–12 months longer than other states." Other aspects worth considering for the next stock price direction are that it could be extra favorable if it coincides with Immunovia's annual general meeting on Wednesday, May 13. But if it's not ready yet, Immunovia needs to keep its cards close to its chest because marketing for New York will set the validation process back, as marketing is strictly forbidden. Other aspects worth noting about it are, quote: "The Psychological 50: Being "Available in all 50 states" allows the company to stop qualifying its marketing. It simplifies the pitch to large national healthcare networks (like Kaiser Permanente or UnitedHealth), who generally won't partner with a lab that can't serve their New York members." "New York Direct-Pay: New York has a massive population of high-net-worth individuals who utilize "concierge medicine." These patients are often willing to pay the $750 - $995 out-of-pocket price while waiting for insurance. Opening New York unlocks this lucrative "cash-pay" segment immediately." "The Synergy: New York approval actually helps the Medicare case. When a company applies for a National Coverage Determination (NCD), having a "clean" 50-state regulatory record prevents administrative delays."
- ·23.4.Pity. But one can probably expect lower daily stock turnover again if the downturn continues in "this way". Now there must surely be some really good news coming soon, right?!!???
- ·21.4. · Muokattuhttps://forum.placera.se/inlagg/52bd8c37-e0eb-4446-a382-8e8fc5d87a80 49 out of 50 states I think it's a bit strange that there was some optimism about New York approval a few days ago. But it has disappeared? It should soon be very close to that event. If one can believe Jeff Borcherding's Q4 optimistic afternoon webcast
- ·16.4. · MuokattuIs there any source for Adob's claim, or is it just "fluff"? https://forum.placera.se/inlagg/c3b44de5-91bc-4a3a-8c83-92e3f7116c98 Quotes: "Adob > Immunovia 1 hour ago They seem to be in full swing to secure a strategic partner to increase growth EXTREMELY IMPORTANT but they should easily find a partner" "Adob Abbot or Roche would fit well" https://forum.placera.se/inlagg/c3b44de5-91bc-4a3a-8c83-92e3f7116c98·16.4. · MuokattuThe risk as I see it is that the wolves in the American financial world are smart enough to wait until Immunovia's cash runs out. Then, when they have the knife to their throat, the wolves can "eat up Immunovia" or buy up the company and their patents for a pittance.·16.4.There is always a risk in a price/demand system. I hope that the management of Immunovia are decent and do not facilitate fraud around corporate actions.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 13 | - | - | ||
| 41 335 | - | - | ||
| 109 | - | - | ||
| 8 556 | - | - | ||
| 19 444 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 3 881 307 | 3 881 307 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 3 881 307 | 3 881 307 | 0 | 0 |